CreatorsPublishersAdvertisers

Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition

Benzinga
Benzinga
 2021-09-21
https://img.particlenews.com/image.php?url=1wyFiB_0c2zsfUw00
  • Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio.
  • Deal terms were not disclosed.
  • Related: Why Did Deutsche Bank Downgrade This Big Pharma Stock?
  • Arctos developed its technology as a potential method for treating inherited retinal dystrophies (IRDs) and other diseases that involve photoreceptor loss, such as age-related macular degeneration.
  • Arctos’ proprietary, light-sensitive optogene is delivered to specific retinal cells using gene therapy, thus turning the targeted cells into replacement photoreceptor-like cells.
  • Arctos was initially incubated by +ND Capital and was later supported by Novartis Venture Fund through a Series A financing round led by +ND Capital.
  • Price Action: NVS stock is up 0.81% at $83.47 during the premarket session on the last check Tuesday.

Comments / 0

Comments / 0